Apimeds Pharmaceuticals US, Inc. Contracts & Agreements
25 Contracts & Agreements
- Business Finance (16 contracts)
- Business Operations (2)
- Human Resources (3)
- Intellectual Property (1)
- Uncategorized (3)
- CFO Consulting Agreement, by and between Apimeds Pharmaceuticals US, Inc. and Mark Corrao, dated October 4, 2024 (Filed With SEC on November 8, 2024)
- Intellectual Property Assignment Agreement by and between Apimeds Pharmaceuticals US, Inc. Apimeds Inc. and Christopher Kim, dated October 12, 2021 (Filed With SEC on September 25, 2024)
- Amended Amendment to the June 2022 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Inscobee Inc., dated June 12, 2024 (Filed With SEC on September 25, 2024)
- Convertible Note Assignment Agreement (March 2022 Promissory Note), by and between Apimeds Pharmaceuticals US, Inc., Apimeds, Inc., and Inscobee Inc., dated June 12, 2024 (Filed With SEC on September 25, 2024)
- Convertible Note Assignment Agreement (August 2021 Promissory Note), by and between Apimeds Pharmaceuticals US, Inc., Apimeds, Inc., and Inscobee Inc., dated June 12, 2024 (Filed With SEC on September 25, 2024)
- May 2024 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Inscobee Inc., dated May 20, 2022 (Filed With SEC on September 25, 2024)
- Advisory Agreement by and between Apimeds Pharmaceuticals US, Inc. and Murdock Capital Partners, dated September 8, 2023 (Filed With SEC on September 25, 2024)
- Loan Agreement by and between Apimeds Pharmaceuticals US, Inc. and Dr. Christopher Kim, dated March 16, 2023 (Filed With SEC on September 25, 2024)
- Loan Agreement by and between Apimeds Pharmaceuticals US, Inc. and Dr. Christopher Kim, dated November 10, 2022 (Filed With SEC on September 25, 2024)
- Loan Agreement by and between Apimeds Pharmaceuticals US, Inc. and Dr. Christopher Kim, dated October 5, 2022 (Filed With SEC on September 25, 2024)
- Form of Indemnification Agreement (Filed With SEC on September 25, 2024)
- Employment Agreement dated September 21, 2023 between Apimeds Pharmaceuticals US, Inc. and Erik Emerson (Filed With SEC on September 25, 2024)
- Patent License Agreement by and between Apimeds Pharmaceuticals US, Inc. and Dr. Christopher Kim, dated October 12, 2021 (Filed With SEC on September 25, 2024)
- Form of Underwriting Agreement (Filed With SEC on September 25, 2024)
- Amendment to the June 2022 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Inscobee Inc., dated December 5, 2023 (Filed With SEC on September 25, 2024)
- June 2022 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Inscobee Inc., dated June 3, 2022 (Filed With SEC on September 25, 2024)
- Amendment to the March 2022 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated December 5, 2023 (Filed With SEC on September 25, 2024)
- March 2022 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated March 21, 2022 (Filed With SEC on September 25, 2024)
- Amendment to the August 2021 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated December 5, 2023 (Filed With SEC on September 25, 2024)
- August 2021 Promissory Note by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated August 30, 2021 (Filed With SEC on September 25, 2024)
- Business Establishment Agreement by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated March 3, 2020 (Filed With SEC on September 25, 2024)
- Apimeds Pharmaceuticals US, Inc. 2024 Equity Incentive Plan (Filed With SEC on September 25, 2024)
- Assignment Agreement by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated October 12, 2021 (Filed With SEC on September 25, 2024)
- Business Agreement by and between Apimeds Pharmaceuticals US, Inc. and Apimeds Inc., dated August 2, 2021 (Filed With SEC on September 25, 2024)
- Letter Agreement by and between Apimeds Pharmaceuticals US, Inc. and Apico Inc., dated November 3, 2021 (Filed With SEC on September 25, 2024)
